Hims & Hers stock has dropped over 60% from its peak due to concerns about its GLP-1 business. Read why I think HIMS stock is ...

As obesity rates rise among individuals with T1D, GLP-1 agonist medications, indicated for T2D and weight loss, are ...

Q4 2024 Earnings Call Transcript March 31, 2025 Rani Therapeutics Holdings, Inc. misses on earnings expectations. Reported EPS is $-0.27 EPS, expectations were $-0.24. Operator: Welcome to the Rani ...

Illustrated on this chart are approved obesity ... we can also spread out the dose. Just one anecdote on that. I was reading about the compounded semaglutide that, that a number of patients ...

Ozempic (semaglutide) and Victoza (liraglutide ... Ozempic and Victoza may cause mild side effects in some people. The following chart lists examples of mild side effects that can most commonly ...

Currently, semaglutide ... listed on the chart, RT-114 and RT-116 are the only proposed orals in development that are expected to utilize similar API quantity and dosing frequency as an injectable ...

Novo Nordisk filed for approval of an oral, 25-mg formulation of its weight loss blockbuster “earlier this year,” according ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. Both ...

Vivani Medical, Inc. (NASDAQ:VANI), on Wednesday, released preclinical data for NPM-139, its subdermal semaglutide implant ... expected once or twice-yearly dosing. Also Read: EXCLUSIVE: Vivani ...

For patients with diabetes, semaglutide use is associated with an increased risk for nonarteritic anterior ischemic optic neuropathy (NAION).